At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 720 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Not stated in record
Key inclusion· 2
- ✓Stable, active plaque psoriasis
- ✓Prior failure with at least one systemic therapy: methotrexate, cyclosporine, PUVA, or fumarate
Key exclusion· 2
- ✕Skin conditions other than psoriasis that would interfere with study evaluations
- ✕Systemic psoriasis therapy within 28 days prior to study entry
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Sep 19, 2005·Updated Feb 25, 2013
In Brief
A Phase 4 clinical trial evaluating Etanercept for Psoriasis. Completed, enrolled 720 participants across 127 sites in 19 countries.
Detailed Summary
This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2004
First PostedSep 2005
Study CompletionFeb 2007
TodayJul 2026
First PostedSep 19, 2005
Enrollment StartDec 1, 2004
Study CompletionFeb 1, 2007
TodayJul 2, 2026
Posted 20.8 years ago
Interventions
Etanerceptdrug